The Safety Study of Autologous TILs Therapy for Patients With Glioblastoma Multiforme.

Inclusion Criteria: 1. Age: 18 to 80 years old; 2. Has at least one measurable tumor foci; 3. ECOG score range : 0-2; 4. Expected survival time: ≥ 3 months; 5. All screening labs should be performed 7 days prior to registration.The laboratory results need to meet below criteria: * Absolute white blood cell counts (WBC) ≥ 3.0×10\^9/L； * Platelet count (PLT) ≥ 100×10\^9/L； * Hematological Absolute neutrophil count (ANC) ≥ 1.5×10\^9/L； * Hemoglobin (HGB) ≥ 90g/L; * Albumin (absolute) ≥ 2.8g/dL; * Serum ALT/AST ≤ 2.5×ULN (for patients with liver metastasis ≤ 5×ULN); * Total bilirubin (TBIL) ≤ 1.5×ULN (for patients with liver metastasis ≤ 2×ULN); * Renal Serum creatinine OR measured or calculated a creatinine clearance (CR) ≤1.5×ULN OR≥ 50 mL/min for participant; * AST/ALT (SGOT) ≤ 2.5×ULN (for patients with liver metastasis ≤ 5×ULN); * International Normalized Ratio (INR) ≤ 1.5; * Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN; 6. Female participant of childbearing potential should have a negative result of human chorionic gonadotropin (HCG) test. The participants must take contraception during the entire clinical follow-up. 7. Be willing and able to provide written informed consent/assent for the trial. Exclusion Criteria: 1. Has systemic active infection and requiring treatment; 2. Has severe physical or mental illness; 3. Has active rheumatic disease; 4. Has any kinds of organ transplantation; 5. Being pregnant or lactating; 6. Enrolled in other clinical trials within 4 weeks prior to registration; 7. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C; 8. Other conditions that the researcher considered to be excluded; 9. Has taken blow treatment before enrollment: * Received systemic immunosuppressive treatments, aside from corticosteroids within 14 days of treatment; * Plan to get inactivated vaccine 28 days prior/during, or 60 days post the treatment.